Patent classifications
A61K33/42
Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.
Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.
Laser assisted wound healing protocol and system
The present invention provides for devices and methods of treating wounds, including general wounds, gum disease and gingival tissues post scaling/root planning, using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm). Further disclosed are devices and methods capable of stimulating tissue regeneration at the site of a wound.
Laser assisted wound healing protocol and system
The present invention provides for devices and methods of treating wounds, including general wounds, gum disease and gingival tissues post scaling/root planning, using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm). Further disclosed are devices and methods capable of stimulating tissue regeneration at the site of a wound.
Pharmaceutical Semi-Solid Gels with Entrapped Calcium Phosphate Nanoparticles
The present disclose generally provides pharmaceutical semi-solid hydrogels with entrapped calcium phosphate Comparison of Fitted Curves with Log Time for nanoparticles that demonstrate enhanced Preparations Demonstrating Statistical Significance drug release, retention, and esthetic properties. The hydrogels are particularly useful for topical applications of drug molecules. The present disclosure also relates to methods of administering a pharmaceutical agent by providing a pharmaceutical semi-solid hydrogel containing at least one pharmaceutical agent and administering it to a subject in need thereof.
Pharmaceutical Semi-Solid Gels with Entrapped Calcium Phosphate Nanoparticles
The present disclose generally provides pharmaceutical semi-solid hydrogels with entrapped calcium phosphate Comparison of Fitted Curves with Log Time for nanoparticles that demonstrate enhanced Preparations Demonstrating Statistical Significance drug release, retention, and esthetic properties. The hydrogels are particularly useful for topical applications of drug molecules. The present disclosure also relates to methods of administering a pharmaceutical agent by providing a pharmaceutical semi-solid hydrogel containing at least one pharmaceutical agent and administering it to a subject in need thereof.
Dimensionally stable molded bone replacement element with residual hydraulic activity
The invention relates to dimensionally stable molded bone replacement elements made of mineral bone cement with residual hydraulic activity that contain at least one share of hardened mineral bone cement and at least one share of unconverted or unhardened reactive mineral bone cement, wherein the share of hardened mineral bone cement is 5% to 90% by weight. The dimensionally stable molded bone replacement elements have at least 5% of the maximum value of the strength of a completely hardened bone cement comprised of the same mineral components and with the same structural characteristics and reach compressive strengths in the range of 2 to 200 MPa. They are substantially free of water and can be converted under biological conditions.
Laser assisted wound healing protocol and system
A method of treating diseased tissue while healing the wound using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate epithelial regeneration when used with or without substrates. A method of treating diseased tissue using a laser light in the green wavelength range (520-570 nm) at a laser power of 0.001 W to 5 W. A method of treating diseased tissue using a laser light in the IR wavelength range (700-1400 nm) at a laser power of 0.001 W to 5 W.
Laser assisted wound healing protocol and system
A method of treating diseased tissue while healing the wound using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate epithelial regeneration when used with or without substrates. A method of treating diseased tissue using a laser light in the green wavelength range (520-570 nm) at a laser power of 0.001 W to 5 W. A method of treating diseased tissue using a laser light in the IR wavelength range (700-1400 nm) at a laser power of 0.001 W to 5 W.
Pharmaceutical composition including laminin fragments to treat or prevent the disease, disorder or symptom of tooth dentin and/or dental pulp
A tooth dentin, pulp or pulp tissue composition for treating or preventing a disease, disorder, or symptom of a tooth dentin and/or pulp or pulp tissue includes: (a) an integrin binding fragment of Laminin, the Laminin being selected from the group consisting of Laminin 511 and Laminin 411, the integrin binding fragment comprising an integrin-binding domain of the Laminin; and (b) a mixture of odontoblast and mineralized nodules secreted from the odontoblast. A coating density of the integrin binding fragment is 1 to 8 μg/cm.sup.2. The material (b) has been mixed with the material (a) in the composition so as to form pulp capping applicable to a tooth, such that the composition is able to treat or prevent the disease, disorder or symptom of the tooth dentin and/or pulp tissue including dental caries when applied to the tooth.